Previous 10 | Next 10 |
2023-08-28 14:55:43 ET More on Esperion Esperion Therapeutics, Inc. ( ESPR ) Q2 2023 Earnings Call Transcript Esperion jumps 15% as BofA double-upgrades citing near-term upside Esperion, Currax team up to co-promote cholesterol lowering drug Nexletol Espe...
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 1...
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MA...
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates on prevention and lipid lowering” at the 2023 ESC Congress taking place August 25-28...
2023-08-01 20:45:25 ET Esperion Therapeutics, Inc. (ESPR) Q2 2023 Earnings Conference Call August 01, 2023, 08:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President and Chief Executive Officer Eric Warren - Chie...
2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...
2023-08-01 06:04:29 ET Esperion Therapeutics press release ( NASDAQ: ESPR ): Q2 GAAP EPS of -$0.46 beats by $0.15 . Revenue of $25.79M (+36.9% Y/Y) beats by $1.15M . Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million Q2 Retail Prescription Equi...
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded Indications in the U.S. and Europe; Label Change...
2023-07-31 13:07:06 ET Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is -$0.63 (+40.0% Y/Y) and the consensus Revenue Estimate is $24.64M (+30.8% Y/Y). Over the...
ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, will participate in a fireside chat on Monday, August 7, 2023 at 9:00 AM ET. The Esperion managem...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...